CAMBRIDGE, Massachusetts
For nearly two decades, flu shots have barely changed. Egg-grown or cell-based, standard-dose or high-dose, they've all relied on essentially the same old-school manufacturing technology — until now. On August 5, the FDA approved mFLUSIVA, Moderna's mRNA-based influenza vaccine, marking the first time in history that mRNA technology — the same platform that powered the COVID-19 vaccines that reached hundreds of millions of arms during the pandemic — has been authorized to fight the flu.
It's being hailed as a milestone moment for vaccine science. But getting here took a wild detour through a regulatory scandal that had public health experts howling, a rare reversal by the FDA itself, and a fight over vaccine policy that is still not fully resolved as the 2026-2027 flu season bears down.
A SHOT DECADES IN THE MAKING
The pitch behind mFLUSIVA is simple but powerful: traditional flu vaccines are built around researchers' best guess, made months in advance, about which flu strains will circulate that season — a guess that, some years, misses badly and leaves the shot only marginally effective. mRNA vaccines, by contrast, can theoretically be updated faster and manufactured more precisely, and Moderna's late-stage trial data suggests the technology may also simply work better against the virus once it's in the body.
In its pivotal Phase 3 trial, mFLUSIVA demonstrated a relative vaccine efficacy roughly 27% higher than a standard-dose comparator flu shot in adults. That's not a marginal improvement — for a virus that hospitalizes hundreds of thousands of Americans and kills tens of thousands more in a typical season, a meaningfully more effective vaccine could translate into real, measurable reductions in flu deaths, particularly among older adults who bear the brunt of severe flu illness every year.
The FDA's approval covers all adults 50 years of age and older, though the agency split the decision into two tiers: full traditional approval for adults ages 50 to 64, and accelerated approval — a conditional pathway typically reserved for promising but not fully proven therapies — for adults 65 and older. That accelerated approval comes with strings attached: Moderna is required to complete a confirmatory postmarketing trial to verify the vaccine's clinical benefit in the oldest and most vulnerable age group, or risk having that portion of the approval pulled.
THE REJECTION THAT SPARKED OUTRAGE
What makes mFLUSIVA's approval so remarkable is what happened just six months earlier. In February 2026, the FDA issued Moderna a rare "refusal-to-file" letter — an unusual move that essentially tells a drugmaker the agency won't even review their application as submitted. The letter, driven by the FDA's Center for Biologics Evaluation and Research under director Dr. Vinay Prasad, argued that Moderna should have tested mFLUSIVA against a high-dose flu vaccine comparator rather than a standard-dose one in its pivotal trial — a much higher bar to clear.
Moderna pushed back hard, noting publicly that the FDA had never flagged that concern as a problem during earlier discussions about the trial's design, effectively changing the rules after the study was already complete. The refusal set off a wave of criticism from vaccine researchers and public health experts, who accused regulators of moving the goalposts on a vaccine that had already shown strong results. Within days, amid that mounting public pressure, the FDA reversed its decision and agreed to formally review the application after all — an unusually public regulatory about-face that left the vaccine's fate hanging in the balance for months.
That messy prelude set the stage for the FDA's Vaccines and Related Biological Products Advisory Committee, or VRBPAC, to convene on June 18, 2026, to formally weigh in. The outcome left little room for doubt about where independent vaccine experts stood: the committee voted unanimously, 9 to 0, to recommend mFLUSIVA for adults 50 to 64 — and then voted 9 to 0 again to recommend it for adults 65 and older. A clean sweep, twice over, from a panel that had every opportunity to hedge.
WHY THIS MATTERS BEYOND JUST ONE FLU SEASON
Public health experts have described the approval as significant for reasons that go well beyond this year's flu numbers. mRNA vaccine technology allows for far more rapid updates to match circulating strains, and manufacturing can, in principle, scale up faster than the egg- or cell-based production methods that have underpinned flu vaccines for generations. Some vaccine researchers have suggested that a successful mRNA flu platform could eventually pave the way toward combination shots — potentially bundling flu, COVID-19, and RSV protection into a single annual mRNA injection, cutting down on the number of separate appointments and needles older adults need each fall.
It also represents a notable commercial and scientific vindication for Moderna, a company whose stock and public standing have been buffeted since the height of the COVID-19 vaccine boom. mFLUSIVA becoming the first mRNA flu vaccine to reach the market — beating rivals like Pfizer, which has also been developing its own mRNA flu candidates — gives Moderna a first-mover advantage in a massive, recurring annual market that egg-based vaccine makers have dominated for decades.
THE CATCH: WILL ANYONE ACTUALLY BE ABLE TO GET IT THIS FALL?
Here's where the story gets complicated, and where the good news runs into a very 2026 problem: FDA approval is only half the battle when it comes to whether Americans will actually receive a new vaccine, and whether insurance will pay for it.
Normally, a Centers for Disease Control and Prevention advisory panel called ACIP — the Advisory Committee on Immunization Practices — meets to formally recommend how and to whom a newly approved vaccine should be given. That recommendation is what typically triggers insurance coverage requirements under federal law, making it just as important commercially as the FDA approval itself. But ACIP has been mired in disruption and internal turmoil for much of 2026, and the committee has not met on its usual schedule amid ongoing disputes over its membership and direction — leaving a real question mark over whether, and how quickly, mFLUSIVA will get the committee recommendation that usually unlocks broad insurance coverage.
That means Moderna is racing to get mFLUSIVA into pharmacies and doctors' offices in time for the 2026-2027 respiratory virus season, even as the policy machinery that normally guarantees smooth, low-cost access to new vaccines remains stuck in neutral. For now, Moderna has said it expects the vaccine to be available for eligible populations this fall, but has not detailed exact pricing, and how much patients will pay out of pocket may depend heavily on how the ACIP situation resolves in the coming weeks.
EXPERT PERSPECTIVE
Vaccine researchers who watched the refusal-to-file saga unfold have pointed to the episode as a stress test for how political and scientific pressures can collide inside federal drug regulation. The unanimous, twice-over VRBPAC vote in June was widely read within the public health community as a strong signal that the underlying science was never seriously in doubt — even as the review process around it became unusually contentious. Advisory committee members who backed the vaccine focused their public comments on the magnitude of the efficacy improvement and the outsized burden flu already places on adults over 50, who account for the vast majority of the roughly 15,000 to 50,000+ flu deaths the CDC estimates occur in a typical U.S. season depending on severity.
Critics, for their part, have raised concerns about the accelerated approval pathway used for the 65-and-older population, arguing that conditional approvals should come with clear timelines and consequences if the confirmatory trial doesn't pan out — a debate that echoes broader tensions in how the FDA has handled accelerated approvals across many drug categories in recent years.
WHAT THIS MEANS FOR YOU
If you're 50 or older, mFLUSIVA represents a genuinely new option worth discussing with your doctor or pharmacist as flu shot season approaches this fall — particularly if you or a loved one has historically gotten a bad case of the flu despite getting vaccinated in past years, since the efficacy improvement Moderna reported specifically addresses that gap. Given the ongoing uncertainty around ACIP and insurance coverage, it's worth calling your pharmacy or insurer in the coming weeks to confirm coverage details before you plan around getting this specific shot rather than a standard flu vaccine.
If you're under 50, mFLUSIVA's approval doesn't currently apply to you, though the door is open for Moderna or competitors to pursue expanded approvals for younger age groups down the line based on how the vaccine performs in the real world this season.
More broadly, this approval is worth watching even if you never get the shot yourself, because it may mark the opening chapter of a broader shift in how flu vaccines — and potentially combination respiratory vaccines — get made every year going forward.
THE BOTTOM LINE
Six months ago, mFLUSIVA looked like it might be dead on arrival, rejected by the very agency meant to evaluate it. Today, it's the first mRNA flu vaccine ever cleared by the FDA, backed by a unanimous expert panel and a meaningfully better efficacy profile than the shots Americans have been getting for decades. Whether that scientific win translates into millions of protected arms this fall now depends less on biology and more on a stalled federal advisory process — a reminder that in American vaccine policy, winning the science is sometimes only step one.
